Latest News
& Press Releases

The long weekend saw BMS’s Opdivo, Novartis’s Kymriah and Roche’s Evrysdi win FDA approvals in new indications.

The initiative, a partnership between non-profit biotech company n-Lorem and Columbia University, focuses on developing personalized experimental ASO medicines for nano-rare ALS patients.

Although there are many mechanisms proposed that contribute to neuroinflammation and damage caused by inflammaging in the brain, INmune Bio has focused on tumor necrosis factor (TNF).

The American Society of Clinical Oncology meeting will be underway next week in Chicago, and companies are preparing to share data from their pipelines. Here’s a look.

Protagonist Therapeutics announced updated promising data from its phase II Revive clinical trial, which is evaluating the safety and efficacy of rusfertide in patients with polycythemia vera (PV).

Bancel’s most recent statements suggest he’s interested in more philanthropy than just his most recent stock option sales.

According to Vision Research Reports, the Molecular Diagnostics market size is expected to hit around US$ 59.3 billion by 2030 and expected to grow at a CAGR of 4.9% during forecast period 2021 to 2030.

Candice Richards, the Manager of Talent Acquisition at Kyowa Kirin North America, shed some light on what to expect from a pharma interview and how to effectively prepare.

TikoMed’s contribution to the fight is ILB, a novel patented formulation of a modified glycosaminoglycan that works to tackle ALS through neurotrophic and myogenic effects.

A roundup of last week’s top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.

Pharma giant Merck announced it is expanding in both area and headcount with a new Cambridge, MA office. The company’s plan is to add 160,000 square feet and 100 new employees.

BioSpace sat down with Gregg Burkhalter, a LinkedIn Expert, for a quick Q&A about the three most common LinkedIn mistakes and how they can affect your personal brand.

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.

• $5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 • $4.5 million of accrued VAT refunds and R&D refundable tax credits from UK subsidiary begin maturing, including $1.9 million VAT cash refund expected in June 2026 • Successful EMA and Australia TGA (ATGA) meetings aligned around use of existing biomarker and pending release of 3-year overall survival data to support Conditional Marketing Authorisations (CMAs) for OST-HER2 in prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma (“Metastatic Osteosarcoma”) • 2.5-year overall survival data expected to be released during ASCO 2026 • EMA and ATGA have aligned on key design aspects of confirmatory Phase 3 Metastatic Osteosarcoma protocol required to have commenced prior to grant of CMAs or FDA BLA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint • Upcoming U.S. FDA Type C meeting and U.K. MHRA SAM meeting to align with EMA & ATGA prior to Australia Clinical Trial Notification submission for Phase 3, including alignment on 3-year overall survival as a primary clinical efficacy endpoint. U.S. FDA (“FDA”) Pre-BLA meeting to confirm alignment on surrogate and primary clinical efficacy endpoints with EMA/ATGA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint, and seek decisions on rolling review acceptance and RMAT designation following the EMA and U.K. MHRA granting ATMP designation (EMA/MHRA RMAT equivalent) for OST-HER2 in Metastatic Osteosarcoma • OS Animal Health S-1 filing for proposed ‘Go-Public’ transaction and receipt of SEC comments